Tuesday, May 23, 2017 11:57:22 AM
CBER Director Focuses on Flexibility to Advance Regenerative Medicines
"The great part of this is this provision (21ST CENTURY CURES ACT)did not lower the safety and effectiveness standard … although we have tremendous flexibility, which we intend to use," Marks said.
"We don't stand on ceremony—forget about the old two randomized controlled trials—single arm, compelling studies are okay in this setting," Marks said, adding that trials of 10 or 20 patients for gene therapy trials for rare diseases may be "compelling enough" for approval, and that the agency could look to creative endpoints for such products.
http://www.raps.org/Regulatory-Focus/News/2017/05/08/27503/CBER-Director-Focuses-on-Flexibility-to-Advance-Regenerative-Medicines/
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM